Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients
Abstract Background In severe traumatic brain injury (TBI), sedatives are often used to control intracranial pressure (ICP), to reduce brain metabolism, to allow for other treatments such as mechanical ventilation or targeted temperature management, or to control paroxysmal sympathetic hyperactivity...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13063-025-08835-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243375527100416 |
|---|---|
| author | Veerle De Sloovere Liese Mebis Pieter Wouters Fabian Guïza Eva Boonen Marc Bourgeois Jasperina Dubois Didier Ledoux Piet Lormans Hugues Maréchal Emmanuel Van der Hauwaert Bart Depreitere Geert Meyfroidt |
| author_facet | Veerle De Sloovere Liese Mebis Pieter Wouters Fabian Guïza Eva Boonen Marc Bourgeois Jasperina Dubois Didier Ledoux Piet Lormans Hugues Maréchal Emmanuel Van der Hauwaert Bart Depreitere Geert Meyfroidt |
| author_sort | Veerle De Sloovere |
| collection | DOAJ |
| description | Abstract Background In severe traumatic brain injury (TBI), sedatives are often used to control intracranial pressure (ICP), to reduce brain metabolism, to allow for other treatments such as mechanical ventilation or targeted temperature management, or to control paroxysmal sympathetic hyperactivity. Prolonged sedation is often necessary. The most commonly used sedatives in TBI are propofol and midazolam, often in combination, but both have significant side effects when used at high doses for several days. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, provides sedation and analgesia with minimal respiratory depression or haemodynamic instability. However, ketamine carries a US Food and Drug Administration (FDA) precaution regarding its use in patients with pre-anaesthetic elevated cerebrospinal fluid pressure, which discourages its use in TBI patients. Several observational studies and two large meta-analyses do not suggest that the use of ketamine as an induction agent or sedative in sedated and mechanically ventilated TBI patients would increase the ICP. Off-label use of ketamine for this indication is increasing worldwide. To date, no prospective randomized clinical trial (RCT) has demonstrated the safety of ketamine in TBI patients. Methods The Brain Injury and Ketamine (BIKe) study is a prospective multicentre double-blind placebo-controlled RCT, to evaluate the safety, and effect on therapeutic intensity to reduce ICP, of ketamine as an adjunct to a standard sedation regimen in patients with severe TBI. Adult TBI patients, admitted to the intensive care unit (ICU), requiring sedation and ICP monitoring within 72 h of admission, will be randomized to ketamine or placebo. The study drug will be started within 6 h of randomization. The dose of the investigational medicinal product (IMP) is 1 mg/kg/h, by continuous infusion. The IMP will be stopped when the last ICP control sedative is discontinued. Data collection will stop when the patient is discharged from the ICU. All patients will be followed for 6 months post-trauma. The study is powered for the safety endpoint of detecting a clinically relevant increase of two episodes in the median number of episodes of high intracranial pressure episodes per ICU stay. A total of 100 patients are required to meet these objectives. We hypothesize a clinically relevant reduction in the therapeutic intensity level (TIL) score of at least 3 points. Discussion This study is the first prospective RCT to investigate the safety of ketamine as an adjunct to a standard sedation regimen in TBI patients. Trial registration ClinicalTrials.gov NCT05097261. Registered on October 28, 2021. |
| format | Article |
| id | doaj-art-d56d963da7db4717b835cc2dfbac250b |
| institution | OA Journals |
| issn | 1745-6215 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj-art-d56d963da7db4717b835cc2dfbac250b2025-08-20T02:00:01ZengBMCTrials1745-62152025-05-0126111110.1186/s13063-025-08835-5Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patientsVeerle De Sloovere0Liese Mebis1Pieter Wouters2Fabian Guïza3Eva Boonen4Marc Bourgeois5Jasperina Dubois6Didier Ledoux7Piet Lormans8Hugues Maréchal9Emmanuel Van der Hauwaert10Bart Depreitere11Geert Meyfroidt12Department of Anesthesiology, University Hospitals LeuvenLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU LeuvenLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU LeuvenLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU LeuvenDepartment of Anesthesiology and Intensive Care MedicineDepartment of Anesthesiology and Intensive Care Medicine, Sint-Jan Brugge-Oostende AVLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU LeuvenDepartment of Intensive Care Medicine, CHU de LiègeDepartment of Intensive Care Medicine, AZ DeltaDepartment of Intensive Care Medicine, CHR La Citadelle LiègeDepartment of Intensive Care Medicine, AZ ImeldaDepartment of Neurosurgery, University Hospitals LeuvenLaboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU LeuvenAbstract Background In severe traumatic brain injury (TBI), sedatives are often used to control intracranial pressure (ICP), to reduce brain metabolism, to allow for other treatments such as mechanical ventilation or targeted temperature management, or to control paroxysmal sympathetic hyperactivity. Prolonged sedation is often necessary. The most commonly used sedatives in TBI are propofol and midazolam, often in combination, but both have significant side effects when used at high doses for several days. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, provides sedation and analgesia with minimal respiratory depression or haemodynamic instability. However, ketamine carries a US Food and Drug Administration (FDA) precaution regarding its use in patients with pre-anaesthetic elevated cerebrospinal fluid pressure, which discourages its use in TBI patients. Several observational studies and two large meta-analyses do not suggest that the use of ketamine as an induction agent or sedative in sedated and mechanically ventilated TBI patients would increase the ICP. Off-label use of ketamine for this indication is increasing worldwide. To date, no prospective randomized clinical trial (RCT) has demonstrated the safety of ketamine in TBI patients. Methods The Brain Injury and Ketamine (BIKe) study is a prospective multicentre double-blind placebo-controlled RCT, to evaluate the safety, and effect on therapeutic intensity to reduce ICP, of ketamine as an adjunct to a standard sedation regimen in patients with severe TBI. Adult TBI patients, admitted to the intensive care unit (ICU), requiring sedation and ICP monitoring within 72 h of admission, will be randomized to ketamine or placebo. The study drug will be started within 6 h of randomization. The dose of the investigational medicinal product (IMP) is 1 mg/kg/h, by continuous infusion. The IMP will be stopped when the last ICP control sedative is discontinued. Data collection will stop when the patient is discharged from the ICU. All patients will be followed for 6 months post-trauma. The study is powered for the safety endpoint of detecting a clinically relevant increase of two episodes in the median number of episodes of high intracranial pressure episodes per ICU stay. A total of 100 patients are required to meet these objectives. We hypothesize a clinically relevant reduction in the therapeutic intensity level (TIL) score of at least 3 points. Discussion This study is the first prospective RCT to investigate the safety of ketamine as an adjunct to a standard sedation regimen in TBI patients. Trial registration ClinicalTrials.gov NCT05097261. Registered on October 28, 2021.https://doi.org/10.1186/s13063-025-08835-5Brain injuryTraumatic woundsKetamineCranio-cerebral traumaCentral nervous systemAnalgesics |
| spellingShingle | Veerle De Sloovere Liese Mebis Pieter Wouters Fabian Guïza Eva Boonen Marc Bourgeois Jasperina Dubois Didier Ledoux Piet Lormans Hugues Maréchal Emmanuel Van der Hauwaert Bart Depreitere Geert Meyfroidt Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients Trials Brain injury Traumatic wounds Ketamine Cranio-cerebral trauma Central nervous system Analgesics |
| title | Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| title_full | Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| title_fullStr | Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| title_full_unstemmed | Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| title_short | Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| title_sort | brain injury and ketamine study bike a prospective randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients |
| topic | Brain injury Traumatic wounds Ketamine Cranio-cerebral trauma Central nervous system Analgesics |
| url | https://doi.org/10.1186/s13063-025-08835-5 |
| work_keys_str_mv | AT veerledesloovere braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT liesemebis braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT pieterwouters braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT fabianguiza braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT evaboonen braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT marcbourgeois braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT jasperinadubois braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT didierledoux braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT pietlormans braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT huguesmarechal braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT emmanuelvanderhauwaert braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT bartdepreitere braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients AT geertmeyfroidt braininjuryandketaminestudybikeaprospectiverandomizedcontrolleddoubleblindclinicaltrialtostudytheeffectsofketamineontherapyintensitylevelandintracranialpressureinseveretraumaticbraininjurypatients |